These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18825512)

  • 41. European Commission approves Fuzeon following FDA approval--first HIV-fusion inhibitor in fight against HIV.
    Infection; 2003 Aug; 31(4):7-8. PubMed ID: 14562955
    [No Abstract]   [Full Text] [Related]  

  • 42. Fuzeon treatment forum, January 2004.
    Burgess GE
    Surviv News (Atlanta Ga); 2004; 15(1):10. PubMed ID: 15032144
    [No Abstract]   [Full Text] [Related]  

  • 43. A delayed hypersensitivity reaction to enfuvirtide after rechallenge.
    Emerson CR; Post JJ; Workman C
    Int J STD AIDS; 2009 Apr; 20(4):288-9. PubMed ID: 19304981
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
    Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
    J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successful desensitization to enfuvirtide after a hypersensitivity reaction in an HIV-1-infected man.
    DeSimone JA; Ojha A; Pathak R; Cohn J
    Clin Infect Dis; 2004 Nov; 39(10):e110-2. PubMed ID: 15546072
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The safety and efficacy of enfuvirtide therapy for HIV infection in patients with hemophilia: a case series.
    Polizzotto MN; Street AM; Wright E
    Clin Infect Dis; 2007 Aug; 45(4):e39-41. PubMed ID: 17638184
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Enfuvirtide in HIV patients: a nursing guideline for medication management].
    Bigler S; Nicca D; Spirig R;
    Pflege; 2009 Feb; 22(1):29-38. PubMed ID: 19173176
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The decision to forgo antiretroviral therapy in people living with HIV compliance as paternalism or partnership?
    Kremer H; Bader A; O'Cleirigh C; Bierhoff HW; Brockmeyer NH
    Eur J Med Res; 2004 Feb; 9(2):61-70. PubMed ID: 15090291
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy.
    Cooper DA; Cordery DV; Reiss P; Henry K; Nelson M; O'Hearn M; Reynes J; Arastéh K; Chung J; Rowell L; Guimaraes D; Bertasso A;
    HIV Med; 2011 Jan; 12(1):31-9. PubMed ID: 20497250
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir.
    Miró O; Garrabou G; López S; Deig E; Vidal I; Infante AB; Cardellach F; Casademont J; Pedrol E
    Antivir Ther; 2006; 11(5):625-30. PubMed ID: 16964831
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study).
    Boyd MA; Truman M; Hales G; Anderson J; Dwyer DE; Carr A
    Antivir Ther; 2008; 13(3):449-53. PubMed ID: 18572758
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration.
    True AL; Chiu YY; Demasi RA; Stout R; Patel I
    Pharmacotherapy; 2006 Dec; 26(12):1679-86. PubMed ID: 17125431
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living.
    Cohen CJ; Dusek A; Green J; Johns EL; Nelson E; Recny MA
    AIDS Patient Care STDS; 2002 Jul; 16(7):327-35. PubMed ID: 12194730
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of darunavir and enfuvirtide in a pregnant woman.
    Sued O; Lattner J; Gun A; Patterson P; Abusamra L; Cesar C; Fink V; Krolewiecki A; Cahn P
    Int J STD AIDS; 2008 Dec; 19(12):866-7. PubMed ID: 19050223
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro characterization of a sustained-release formulation for enfuvirtide.
    Rothstein SN; Huber KD; Sluis-Cremer N; Little SR
    Antimicrob Agents Chemother; 2014; 58(3):1797-9. PubMed ID: 24366751
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Needle-free Fuzeon in works.
    AIDS Patient Care STDS; 2005 Sep; 19(9):614. PubMed ID: 16164388
    [No Abstract]   [Full Text] [Related]  

  • 57. Fuzeon-induced collagenophagic granuloma: a peculiar granulomatous injection site reaction to Fuzeon--a case report and review of literature.
    Sidhu HK; Chaffee BH; Tvetenstrand CD; Sidhu JS
    Int J Surg Pathol; 2010 Oct; 18(5):384-7. PubMed ID: 19223380
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.
    Lalezari JP; Patel IH; Zhang X; Dorr A; Hawker N; Siddique Z; Kolis SJ; Kinchelow T
    J Clin Virol; 2003 Oct; 28(2):217-22. PubMed ID: 12957192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enfuvirtide injection site reactions: a clinical and histopathological appraisal.
    Wallace BJ; Tan KB; Pett SL; Cooper DA; Kossard S; Whitfeld MJ
    Australas J Dermatol; 2011 Feb; 52(1):19-26. PubMed ID: 21332688
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks.
    Cohen C; Hellinger J; Johnson M; Staszewski S; Wintfeld N; Patel K; Green J
    HIV Clin Trials; 2003; 4(5):347-57. PubMed ID: 14583851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.